Possible anticancer activity of rosuvastatine, doxazosin, repaglinide and oxcarbazepin

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 199-203

  El Sharkawi, Fathia Zaky ^a   El Shemy, Hany Abdelaziz ^b   Khaled, Hussein Moustafa ^c  

^a Helwan University   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Cell lines; Doxazosin; In vitro anticancer chemosensitivity; Oxcarbazepin; Repaglinide; Rosuvastatine

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CARBAMIC ACID DERIVATIVE; DOXAZOSIN; DRUG DERIVATIVE; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXCARBAZEPINE; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; REPAGLINIDE; ROSUVASTATIN; SULFONAMIDE;

ANIMAL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECT; EHRLICH ASCITES TUMOR; HELA CELL LINE; HEPG2 CELL LINE; HUMAN; IC 50; MCF 7 CELL LINE;

ANIMALS; ANTICONVULSANTS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; CARBAMATES; CARBAMAZEPINE; CARCINOMA, EHRLICH TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOXAZOSIN; FLUOROBENZENES; HELA CELLS; HEP G2 CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; PIPERIDINES; PYRIMIDINES; SULFONAMIDES;

EID: 84894041324     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.199     Document Type: Article

References (25)

1. Aguilar-Salinas CA, Barrett H, Schonfeld G (1993). Metabolic modes ofaction of the statins in the hyperlipoproteinemias. Atherosclerosis, 141, 203-7.
2. Arencibia JM, Del Rio M, Bonnin A, et al (2005). Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation. Int J Oncol, 27, 1617-23.
3. Bader T, Fazili J, Madhoum M, et al (2008). Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol, 103, 1383-9.
4. Bennett JM, Catovsky D, Danniel MT, et al (1976). Proposal for the classification of the acute leukemia. Br J Heam, 33, 451-8.
5. Campos-Lara M and Mendoza-Espinoza JA (2011). Cytotoxic evaluation of fluvastatin and rosuvastatin and effect of fluvastatin in the hela cell cycle. African J Pharm Pharmacol, 5, 189-93.
6. Cansu A, Erdogan D, Serdaroglu A, et al (2010). Histologic and morphologic effects of valproic acid and oxcarbazepine on rat uterine and ovarian cells. Epilepsia, 51, 98-107.
7. Chan KWK, Oza MA, Siu LL (2003). The statins as anticancer agents. Clin Cancer Res, 9, 10-19.
8. Chiang CF, Son EL,Wu GJ (2005). Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis. Prostate, 64, 408-18.
9. Feng YH, Velazquez-Torres G, Gully C, et al (2011). The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med, 15, 825-36.
10. Garrison JB, Kyprianou N (2006). Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res, 66, 464-72.
11. Gan L, Zhu DX, Yang LP, et al (2008). Involvement of transcription factor activator protein-2alpha in doxazosin-induced HeLa cell apoptosis. Acta Pharmacol Sin, 29, 465-72.
12. Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury G (2010). Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal, 22, 749-58.
13. Glozak MA, Seto E (2007). Histone deacetylases and cancer. Oncogene, 26, 5420-32.
14. Hui H, Fernando MA, Heaney AP (2008). The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signaling to induce breast cancer cell apoptosis. Eur J Cancer, 44, 160-6.
15. Landgraf R (2000). Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging, 17, 411-25.
16. Nielsen SF, Nordestgaard BG, Bojesen SE (2012). Statin use and reduced cancer-related mortality. N Engl J Med, 367, 1792-802.
17. Partin JV, Anglin IE, Kyprianou N (2003). Quinazoline-based a1 adrenoceptor antagonists induce prostate cancer cell apoptosis viaTGF-b signaling and I kappa B a induction. Br J Cancer, 88, 1615-21.
18. Qian X, Li J, Ding JM, et al (2008).Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803. Biochem Pharmacol, 76, 1705-15.
19. Repetto G, Peso A, Zurita J (2008). Neutral red uptake assay for the estimation of cell viability /cytotoxicity. Nature Protocols, 3, 1125-31.
20. Seo M, Inoue I, Ikeda M, et al (2008). Statins activate human PPAR promoter and increase PPAR mRNA expression and activation in HepG2 cells. PPAR-Res, 2008, 11.
21. Shaw YJ, Yang YT, Garrison JB, et al (2004). Pharmacological exploitation of the a1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J Med Chem, 47, 4453-62.
22. Stettner M, Krämer G, Strauss A, et al (2012). Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. Eur J Cancer Prev, 21, 55-64.
23. Takahashi HK, Weitz-Schmidt G, Iwagaki H, et al (2006). Hypothesis: The antitumor activities of statins may be mediated by IL18. J Leukoc Biol, 80, 215-6.
24. Traxler P (2003). Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin Ther Targets, 7, 215-34.
25. Walden PD, Globina Y, Nieder A (2004). Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase 3 and a reduction of focal adhesion kinase. Urol Res, 32, 261-5.